香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確 性或完整性亦不發表任何聲明，並表明概不就因本公告全部或任何部分內容而產生或因依賴 該等內容而引致的任何損失承擔任何責任。 史文玲 （ 於 中 華 人 民 共 和 國 註 冊 成 立 的 股 份 有 限 公 司 ） 中國，北京，2025年10月22日 （股 份 代 號：1858） 截至本公告日期，執行董事為史文玲女士、史春寶先生、岳術俊女士及解鳳寶先生；非執行 董事為王鑫先生；及獨立非執行董事為徐泓女士、黃德盛先生及翁杰先生。 北京市春立正達醫療器械股份有限公司（「本公司」）之董事會（「董事會」）謹此 宣佈將於2025年10月30日（星期四）舉行董事會會議，藉以（其中包括）批准本公 司及其附屬公司截至2025年9月30日止九個月之第三季度業績公佈及考慮派付 中期股息（如有）。 代表董事會 北京市春立正達醫療器械股份有限公司 北 京 市 春 立 正 達 醫 療 器 械 股 份 有 限 公 司 Beijing Chunlizhengda Medical Instruments Co., Ltd.* 董事長 董事會會議通告 * 僅供識別 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確 性或完整性亦不發表任何聲明，並表明概不就因本公告全部或任何部分內容而產生或因依賴 該等內容而引致的任何損失承擔任何責任。 北 京 市 春 立 正 達 醫 療 器 械 股 份 有 限 公 司 Beijing Chunlizhengda Medical Instruments Co., Ltd.* （ 於 中 華 人 民 共 和 國 註 冊 成 立 的 股 份 有 限 公 司 ） （股 份 代 號：1858） 代表董事會 北京市春立正達醫療器械股份有限公司 董事長 史文玲 中國，北京，2025年10月22日 截至本公告日期，執行董事為史文玲女士、史春寶先生、岳術俊女士及解鳳寶先生；非執行 董事為王鑫先生；及獨立非執行董事為徐泓女士、黃德盛先生及翁杰先生。 * 僅供識別 董事會會議通告 北京市春立正達醫療器械股份有限公司（「本公司」）之董事會（「董事會」）謹此 宣佈將於2025年10月30日（星期四）舉行董事會會議，藉以（其中包括）批准本公 司及其附屬公司截至2025年9月30日止九個月之第三季度業績公佈及考慮派付 中期股息（如有）。 ...

Core Viewpoint - Spring Medical has seen a significant stock price increase of 18.98% over the past five days, closing at 28.48 CNY per share, with a market capitalization of 10.924 billion CNY [1] Company Overview - Beijing Spring Medical Co., Ltd. specializes in the research, production, and sales of implantable orthopedic medical devices, primarily focusing on joint prosthetics and spinal implants [1] - The company was established on February 12, 1998, and went public on December 30, 2021 [1] - The main revenue source is from medical device products, accounting for 99.89% of total revenue, with a minor contribution from other sources [1] Shareholder Insights - Ping An Fund's Low Carbon Economy Mixed A Fund (009878) is among the top ten shareholders of Spring Medical, having increased its holdings by 2.77 million shares in the second quarter [2] - The fund currently holds 3.77 million shares, representing 0.98% of the circulating shares, with a floating profit of approximately 5.278 million CNY as of the latest report [2][4] - Over the five-day stock price increase, the fund's floating profit reached 16.2864 million CNY [2][4] Fund Performance - The Low Carbon Economy Mixed A Fund has a total asset size of 1.427 billion CNY and has achieved a year-to-date return of 27.73% [2] - The fund's one-year return stands at 23.92%, ranking 3413 out of 8026 in its category [2] - The fund manager, He Jie, has a tenure of 7 years and 196 days, with the best fund return during this period being 222.53% [3]

来源：新浪证券-红岸工作室 10月21日，春立医疗涨0.74%，成交额1.14亿元。两融数据显示，当日春立医疗获融资买入额1481.85万 元，融资偿还782.54万元，融资净买入699.31万元。截至10月21日，春立医疗融资融券余额合计4238.89 万元。 融资方面，春立医疗当日融资买入1481.85万元。当前融资余额4238.89万元，占流通市值的0.54%，融 资余额超过近一年90%分位水平，处于高位。 融券方面，春立医疗10月21日融券偿还0.00股，融券卖出0.00股，按当日收盘价计算，卖出金额0.00 元；融券余量0.00股，融券余额0.00元，超过近一年70%分位水平，处于较高位。 资料显示，北京市春立正达医疗器械股份有限公司位于北京市通州区通州经济开发区南区鑫觅西二路10 号，成立日期1998年2月12日，上市日期2021年12月30日，公司主营业务涉及北京市春立正达医疗器械 股份有限公司是一家主要从事植入性骨科医疗器械研发、生产及销售业务的中国公司。该公司主要产品 为关节假体产品及脊柱类植入产品。关节假体产品涵盖髋、膝、肩、肘四大人体关节。脊柱类植入产品 为脊柱内固定系统的全系列产品组合 ...

Market Overview - The medical device sector increased by 0.28% on October 20, with Chunli Medical leading the gains [1] - The Shanghai Composite Index closed at 3863.89, up 0.63%, while the Shenzhen Component Index closed at 12813.21, up 0.98% [1] Top Gainers in Medical Device Sector - Chunli Medical (688236) closed at 26.88, up 8.17% with a trading volume of 49,900 shares and a turnover of 128 million yuan [1] - Laijing Co. (301093) closed at 36.89, up 7.52% with a trading volume of 63,700 shares and a turnover of 234 million yuan [1] - Aipeng Medical (300753) closed at 30.69, up 7.42% with a trading volume of 127,900 shares and a turnover of 388 million yuan [1] - Other notable gainers include Canar Co. (301122) up 6.07%, Zhend Medical (603301) up 5.93%, and Haooubo (688656) up 5.15% [1] Top Losers in Medical Device Sector - Toukeng Life (300642) closed at 27.30, down 3.12% with a trading volume of 182,000 shares and a turnover of 506 million yuan [2] - Rejing Bio (688068) closed at 177.83, down 2.44% with a trading volume of 26,400 shares and a turnover of 468 million yuan [2] - Yingke Medical (300677) closed at 42.01, down 2.21% with a trading volume of 301,700 shares and a turnover of 1.261 billion yuan [2] Capital Flow Analysis - The medical device sector experienced a net outflow of 599 million yuan from institutional investors, while retail investors saw a net inflow of 513 million yuan [2] - The sector's overall capital flow indicates a mixed sentiment, with institutional investors withdrawing funds while retail investors are actively buying [2] Individual Stock Capital Flow - Lepu Medical (300003) had a net inflow of 40.93 million yuan from institutional investors, while retail investors saw a net outflow of 32.18 million yuan [3] - Lino Pharmaceutical (301188) experienced a net inflow of 16.44 million yuan from institutional investors, with retail investors also seeing a net outflow of 15.07 million yuan [3] - Huatai Medical (688617) had a net inflow of 15.70 million yuan from institutional investors, while retail investors faced a net outflow of 3.08 million yuan [3]

Core Viewpoint - Spring Medical experienced an 8.17% increase in stock price on October 20, with a trading volume of 128 million yuan and a market capitalization of 10.31 billion yuan [1] Company Overview - Spring Medical is a leading domestic manufacturer of orthopedic medical devices, focusing on the research, production, and sales of implantable orthopedic medical devices, including oral metal and invisible orthodontics, as well as oral implants and restorations [2][5] - The company is recognized as a "specialized, refined, distinctive, and innovative" small giant enterprise, which signifies its strong innovation capabilities and high market share in niche markets [3] - The company is located in Tongzhou District, Beijing, and was established on February 12, 1998, with its stock listed on December 30, 2021 [7][8] Product Portfolio - Spring Medical's main products include joint prosthetics and spinal implants, covering major human joints such as hip, knee, shoulder, and elbow, as well as a full range of spinal internal fixation systems [2][8] - The company has developed a customized porous tantalum dental implant product, which is currently in the design and inspection phase [2] Financial Performance - For the first half of 2025, Spring Medical achieved a revenue of 488 million yuan, representing a year-on-year growth of 28.27%, and a net profit attributable to shareholders of 114 million yuan, up 44.85% year-on-year [8] - Since its A-share listing, the company has distributed a total of 359 million yuan in dividends, with 309 million yuan distributed over the past three years [8] Market Position - The company is part of the pharmaceutical and biological industry, specifically in the medical device and consumables sector, and is involved in various concept sectors including H-shares, share buybacks, new materials, and robotics [8] - As of June 30, 2025, the number of shareholders decreased by 17.57% to 5,920, while the average circulating shares per person increased by 341.41% to 48,836 shares [8][9]

融券方面，春立医疗10月17日融券偿还0.00股，融券卖出0.00股，按当日收盘价计算，卖出金额0.00 元；融券余量0.00股，融券余额0.00元，超过近一年70%分位水平，处于较高位。 资料显示，北京市春立正达医疗器械股份有限公司位于北京市通州区通州经济开发区南区鑫觅西二路10 号，成立日期1998年2月12日，上市日期2021年12月30日，公司主营业务涉及北京市春立正达医疗器械 股份有限公司是一家主要从事植入性骨科医疗器械研发、生产及销售业务的中国公司。该公司主要产品 为关节假体产品及脊柱类植入产品。关节假体产品涵盖髋、膝、肩、肘四大人体关节。脊柱类植入产品 为脊柱内固定系统的全系列产品组合。该公司的产品出口至亚洲、南美洲、非洲、大洋洲及欧洲等多个 国家和地区。主营业务收入构成为：医疗器械产品99.89%，其他(补充)0.11%。 10月17日，春立医疗涨1.47%，成交额1.08亿元。两融数据显示，当日春立医疗获融资买入额754.25万 元，融资偿还1068.99万元，融资净买入-314.74万元。截至10月17日，春立医疗融资融券余额合计 3134.41万元。 来源：新浪证券-红岸工作室 融资方面 ...

Core Viewpoint - Spring Medical has seen a significant stock price increase of 9.18% over the past three days, indicating strong market interest and potential growth in the orthopedic medical device sector [1] Company Overview - Beijing Spring Medical Co., Ltd. specializes in the research, production, and sales of implantable orthopedic medical devices, with a focus on joint prosthetics and spinal implants [1] - The company was established on February 12, 1998, and went public on December 30, 2021 [1] - Its main products include hip, knee, shoulder, and elbow joint prosthetics, as well as a full range of spinal fixation systems [1] - The company exports its products to various regions, including Asia, South America, Africa, Oceania, and Europe [1] - The revenue composition is primarily from medical device products (99.89%) with a minor contribution from other sources (0.11%) [1] Shareholder Information - Southern Fund's Southern Medical Health Flexible Allocation Mixed A Fund (000452) is among the top ten circulating shareholders of Spring Medical, holding 1.603 million shares, which is 0.42% of the circulating shares [2] - The fund has realized a floating profit of approximately 2.0518 million yuan today and 3.3503 million yuan during the three-day price increase [2] - The fund was established on January 23, 2014, and has a current scale of 2.405 billion yuan, with a year-to-date return of 43.87% [2] Fund Management - The fund manager of Southern Medical Health Flexible Allocation Mixed A is Cai Qiang, who has been in the position for 2 years and 128 days [3] - The total asset size of the fund is 4.213 billion yuan, with the best return during his tenure being 21.06% and the worst being 0% [3]

截至6月30日，春立医疗股东户数5920.00，较上期减少17.57%；人均流通股48836股，较上期增加 341.41%。2025年1月-6月，春立医疗实现营业收入4.88亿元，同比增长28.27%；归母净利润1.14亿元， 同比增长44.85%。 分红方面，春立医疗A股上市后累计派现3.59亿元。近三年，累计派现3.09亿元。 机构持仓方面，截止2025年6月30日，春立医疗十大流通股东中，平安低碳经济混合A（009878）位居 第四大流通股东，持股377.00万股，相比上期增加277.00万股。南方医药保健灵活配置混合A （000452）位居第九大流通股东，持股160.30万股，为新进股东。中庚小盘价值股票（007130）、香港 中央结算有限公司、中庚价值先锋股票（012930）退出十大流通股东之列。 来源：新浪证券-红岸工作室 春立医疗今年以来股价涨99.04%，近5个交易日涨10.68%，近20日涨6.19%，近60日涨31.50%。 10月20日，春立医疗盘中上涨2.13%，截至09:36，报25.38元/股，成交1145.00万元，换手率0.16%，总 市值97.35亿元。 资料显示，北京市春立 ...

Industry Investment Rating - The report maintains an investment rating of "Outperform" for the orthopedic consumables sector [2]. Core Insights - The orthopedic consumables sector experienced significant performance improvement in H1 2025, with a positive trend in overseas expansion and accelerated corporate layouts [3][5]. - The overall revenue of the A-share orthopedic consumables sector increased by 16% year-on-year in H1 2025, with net profit attributable to shareholders rising by 70% and non-recurring net profit increasing by 75% [5][11]. - The gross profit margin for the sector was 66% in H1 2025, reflecting a year-on-year increase of 1.95 percentage points, attributed to ongoing cost control and optimization [5][11]. - The report highlights a favorable trend in overseas business, which is expected to become a significant growth driver for companies in the sector [5][35]. Summary by Sections 1. Orthopedic Consumables H1 2025 Report Analysis - The orthopedic consumables sector saw a revenue increase of 16.24% in H1 2025, with a gross profit margin of 66.07% [9][11]. - The second quarter of 2025 showed a revenue growth of 23% year-on-year, with net profit growth of 84% [11]. 2. Segment Analysis - The joint business segment benefited from the implementation of centralized procurement policies, leading to a sustained increase in both volume and price for leading companies [22]. - The spinal segment is experiencing stable execution of centralized procurement, with significant room for domestic companies to increase market share [29]. 3. Related Company Summaries - **Dabo Medical**: Achieved a revenue of 12.1 billion yuan in H1 2025, a year-on-year increase of 25.55%, with a net profit of 2.44 billion yuan, up 76.69% [41]. - **Weigao Orthopedics**: Reported a revenue of 7.41 billion yuan in H1 2025, a slight decrease of 1.28%, but net profit increased by 52.43% [57]. - **Aikang Medical**: Generated a revenue of 6.94 billion yuan in H1 2025, reflecting a growth of 5.65% year-on-year [47]. - **Chunli Medical**: Recorded a revenue of 4.88 billion yuan in H1 2025, up 28.27% year-on-year [52]. - **Sanyou Medical**: Achieved a revenue of 2.50 billion yuan in H1 2025, a year-on-year increase of 17.77% [61].